JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature
Cutaneous T-cell lymphomas (CTCLs) are a group of lymphoid neoplasms with high relapse rates and no curative treatment other than allogeneic stem cell transplantation (allo-SCT). CTCL is significantly influenced by disruption of JAK/STAT signaling. Therefore, Janus kinase (JAK) inhibitors may be pro...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/5/861 |
| _version_ | 1797264812352208896 |
|---|---|
| author | Seyed Mohammad Vahabi Saeed Bahramian Farzad Esmaeili Bardia Danaei Yasamin Kalantari Patrick Fazeli Sara Sadeghi Nima Hajizadeh Chalid Assaf Ifa Etesami |
| author_facet | Seyed Mohammad Vahabi Saeed Bahramian Farzad Esmaeili Bardia Danaei Yasamin Kalantari Patrick Fazeli Sara Sadeghi Nima Hajizadeh Chalid Assaf Ifa Etesami |
| author_sort | Seyed Mohammad Vahabi |
| collection | DOAJ |
| description | Cutaneous T-cell lymphomas (CTCLs) are a group of lymphoid neoplasms with high relapse rates and no curative treatment other than allogeneic stem cell transplantation (allo-SCT). CTCL is significantly influenced by disruption of JAK/STAT signaling. Therefore, Janus kinase (JAK) inhibitors may be promising for CTCL treatment. This study is a systematic review aiming to investigate the role of JAK inhibitors in the treatment of CTCL, including their efficacy and safety. Out of 438 initially searched articles, we present 13 eligible ones. The overall response rate (ORR) in the treatment with JAK inhibitors in clinical trials was 11–35%, although different subtypes of CTCL showed different ORRs. Mycosis fungoides showed an ORR of 14–45%, while subcutaneous-panniculitis-like T-cell lymphoma (SPTCL) displayed an ORR ranging from 75% to 100%. Five cases were reported having a relapse/incident of CTCL after using JAK inhibitors; of these, three cases were de novo CTCLs in patients under treatment with a JAK inhibitor due to refractory arthritis, and two cases were relapsed disease after graft-versus-host disease treatment following allo-SCT. In conclusion, using JAK inhibitors for CTCL treatment seems promising with acceptable side effects, especially in patients with SPTCL. Some biomarkers, like pS6, showed an association with better responses. Caution should be taken when treating patients with an underlying autoimmune disease and prior immunosuppression. |
| first_indexed | 2024-04-25T00:34:51Z |
| format | Article |
| id | doaj.art-df7e829dbd6a4a22a8a9adf1ef7e6a24 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-04-25T00:34:51Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-df7e829dbd6a4a22a8a9adf1ef7e6a242024-03-12T16:40:37ZengMDPI AGCancers2072-66942024-02-0116586110.3390/cancers16050861JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published LiteratureSeyed Mohammad Vahabi0Saeed Bahramian1Farzad Esmaeili2Bardia Danaei3Yasamin Kalantari4Patrick Fazeli5Sara Sadeghi6Nima Hajizadeh7Chalid Assaf8Ifa Etesami9School of Medicine, Tehran University of Medical Sciences, Tehran 1461884513, IranSchool of Medicine, Isfahan University of Medical Sciences, Isfahan 8174673461, IranSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717411, IranSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717411, IranSchool of Medicine, Tehran University of Medical Sciences, Tehran 1461884513, IranIndependent Researcher, Agoura Hills, CA 91301, USASchool of Medicine, Iran University of Medical Sciences, Tehran 1449614535, IranSchool of Medicine, Iran University of Medical Sciences, Tehran 1449614535, IranDepartment of Dermatology and Venerology, Helios Klinikum Krefeld, 47805 Krefeld, GermanyDepartments of Dermatology, Razi Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran 1983969411, IranCutaneous T-cell lymphomas (CTCLs) are a group of lymphoid neoplasms with high relapse rates and no curative treatment other than allogeneic stem cell transplantation (allo-SCT). CTCL is significantly influenced by disruption of JAK/STAT signaling. Therefore, Janus kinase (JAK) inhibitors may be promising for CTCL treatment. This study is a systematic review aiming to investigate the role of JAK inhibitors in the treatment of CTCL, including their efficacy and safety. Out of 438 initially searched articles, we present 13 eligible ones. The overall response rate (ORR) in the treatment with JAK inhibitors in clinical trials was 11–35%, although different subtypes of CTCL showed different ORRs. Mycosis fungoides showed an ORR of 14–45%, while subcutaneous-panniculitis-like T-cell lymphoma (SPTCL) displayed an ORR ranging from 75% to 100%. Five cases were reported having a relapse/incident of CTCL after using JAK inhibitors; of these, three cases were de novo CTCLs in patients under treatment with a JAK inhibitor due to refractory arthritis, and two cases were relapsed disease after graft-versus-host disease treatment following allo-SCT. In conclusion, using JAK inhibitors for CTCL treatment seems promising with acceptable side effects, especially in patients with SPTCL. Some biomarkers, like pS6, showed an association with better responses. Caution should be taken when treating patients with an underlying autoimmune disease and prior immunosuppression.https://www.mdpi.com/2072-6694/16/5/861cutaneous T-cell lymphomasCTCLJanus kinaseJAK inhibitormycosis fungoidessubcutaneous panniculitis-like T-cell lymphoma |
| spellingShingle | Seyed Mohammad Vahabi Saeed Bahramian Farzad Esmaeili Bardia Danaei Yasamin Kalantari Patrick Fazeli Sara Sadeghi Nima Hajizadeh Chalid Assaf Ifa Etesami JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature Cancers cutaneous T-cell lymphomas CTCL Janus kinase JAK inhibitor mycosis fungoides subcutaneous panniculitis-like T-cell lymphoma |
| title | JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature |
| title_full | JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature |
| title_fullStr | JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature |
| title_full_unstemmed | JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature |
| title_short | JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature |
| title_sort | jak inhibitors in cutaneous t cell lymphoma friend or foe a systematic review of the published literature |
| topic | cutaneous T-cell lymphomas CTCL Janus kinase JAK inhibitor mycosis fungoides subcutaneous panniculitis-like T-cell lymphoma |
| url | https://www.mdpi.com/2072-6694/16/5/861 |
| work_keys_str_mv | AT seyedmohammadvahabi jakinhibitorsincutaneoustcelllymphomafriendorfoeasystematicreviewofthepublishedliterature AT saeedbahramian jakinhibitorsincutaneoustcelllymphomafriendorfoeasystematicreviewofthepublishedliterature AT farzadesmaeili jakinhibitorsincutaneoustcelllymphomafriendorfoeasystematicreviewofthepublishedliterature AT bardiadanaei jakinhibitorsincutaneoustcelllymphomafriendorfoeasystematicreviewofthepublishedliterature AT yasaminkalantari jakinhibitorsincutaneoustcelllymphomafriendorfoeasystematicreviewofthepublishedliterature AT patrickfazeli jakinhibitorsincutaneoustcelllymphomafriendorfoeasystematicreviewofthepublishedliterature AT sarasadeghi jakinhibitorsincutaneoustcelllymphomafriendorfoeasystematicreviewofthepublishedliterature AT nimahajizadeh jakinhibitorsincutaneoustcelllymphomafriendorfoeasystematicreviewofthepublishedliterature AT chalidassaf jakinhibitorsincutaneoustcelllymphomafriendorfoeasystematicreviewofthepublishedliterature AT ifaetesami jakinhibitorsincutaneoustcelllymphomafriendorfoeasystematicreviewofthepublishedliterature |